LTS - 4 Mid-Market Banks Powering Advancements In Healthcare
Investment banks generate handsome revenues by advising and facilitating the financing of innovative biotech and life sciences companies. Most research and development stage biotechs produce no revenue, causing them to regularly return to investors for additional capital. With drug development price tags ranging from several hundred million to $2.5 billion, bankers fiercely compete to get a piece of the hefty fees when it's time to raise more money.
Household names like Citigroup, Goldman Sachs, JP Morgan Chase, and Morgan Stanley handle the biggest, most promising IPOs and financing rounds. Below this tier, several middle market investment banks tailor their offerings to micro, small, and mid-cap life sciences companies.
Image Source: Getty Images